Model utilities
| Utilities . | Health states with assigned utility . | QALY . | Range . | Reference . |
|---|---|---|---|---|
| PFS, oral treatment | Ibrutinib 1L R-venetoclax | 0.71 | 0.67-0.75 | 43 |
| PFS, IV treatment | R-bendamustine | 0.67 | 0.63-0.71 | 43 |
| PFS, no treatment (after first-line) | After completion of R-bendamustine or discontinuation of ibrutinib 1L or R-bendamustine because of AE | 0.82 | 0.78-0.85 | 43 |
| PFS, no treatment (after second-line or later) | After completion of R-venetoclax or discontinuation of ibrutinib 3L because of AE | 0.71 | 0.66-0.75 | 43 |
| Progression after first-line therapy | After progression from R-bendamustine, before starting second-line therapy | 0.66 | 0.62-0.71 | 43 |
| Progression after second-line therapy | After progression from R-venetoclax, before starting third-line therapy | 0.59 | 0.55-0.64 | 43 |
| PFS, third-line therapy | Ibrutinib 3L R-idelalisib (first-line ibrutinib arm) | 0.55 | 0.50-0.60 | 43 |
| PFS, fourth-line therapy | R-idelalisib (delayed ibrutinib arm) Ofatumumab | 0.42 | 0.37-0.47 | 43 |
| Relapsed lines of treatment | Best supportive care | 0.42 | 0.37-0.47 | 43 |
| Utilities . | Health states with assigned utility . | QALY . | Range . | Reference . |
|---|---|---|---|---|
| PFS, oral treatment | Ibrutinib 1L R-venetoclax | 0.71 | 0.67-0.75 | 43 |
| PFS, IV treatment | R-bendamustine | 0.67 | 0.63-0.71 | 43 |
| PFS, no treatment (after first-line) | After completion of R-bendamustine or discontinuation of ibrutinib 1L or R-bendamustine because of AE | 0.82 | 0.78-0.85 | 43 |
| PFS, no treatment (after second-line or later) | After completion of R-venetoclax or discontinuation of ibrutinib 3L because of AE | 0.71 | 0.66-0.75 | 43 |
| Progression after first-line therapy | After progression from R-bendamustine, before starting second-line therapy | 0.66 | 0.62-0.71 | 43 |
| Progression after second-line therapy | After progression from R-venetoclax, before starting third-line therapy | 0.59 | 0.55-0.64 | 43 |
| PFS, third-line therapy | Ibrutinib 3L R-idelalisib (first-line ibrutinib arm) | 0.55 | 0.50-0.60 | 43 |
| PFS, fourth-line therapy | R-idelalisib (delayed ibrutinib arm) Ofatumumab | 0.42 | 0.37-0.47 | 43 |
| Relapsed lines of treatment | Best supportive care | 0.42 | 0.37-0.47 | 43 |
1L, first-line; 3L, third line.